Anaptysbio (ANAB) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $46.61, -4.31% vs the prior close of $48.71.
- Volume 413.63K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ANAB slides 4.3% to $46.61. Closed at $46.61, -4.31% vs the prior close of $48.71. Day range $46.46–$48.56, opened at $48.56.
ANAB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ANAB slides 4.3% to $46.61
- Closed at $46.61, -4.31% vs the prior close of $48.71. Day range $46.46–$48.56, opened at $48.56.
- Volume was 413.63K shares, 0.8x its 50-day average of 494.05K.
- Price is -13.0% vs its 50-day average ($53.57) and -5.9% vs its 200-day average ($49.52).
- 52-week range $20.18–$72.36; today's close sits at 51% of that range, 35.6% below the 52-week high.
Oct 15, 2026 — ANAB jumps 4.4% to $48.71
- Closed at $48.71, +4.37% vs the prior close of $46.67. Day range $46.93–$48.83, opened at $47.43.
- Volume was 416.30K shares, 0.8x its 50-day average of 492.06K.
- Price is -9.4% vs its 50-day average ($53.74) and -1.5% vs its 200-day average ($49.44).
- 52-week range $20.18–$72.36; today's close sits at 55% of that range, 32.7% below the 52-week high.
Oct 14, 2026 — ANAB rises 2.4% to $46.67
- Closed at $46.67, +2.37% vs the prior close of $45.59. Day range $45.00–$47.24, opened at $45.25.
- Volume was 494.10K shares, 1.0x its 50-day average of 490.53K.
- Price is -13.4% vs its 50-day average ($53.86) and -5.5% vs its 200-day average ($49.37).
- 52-week range $20.18–$72.36; today's close sits at 51% of that range, 35.5% below the 52-week high.
Oct 13, 2026 — ANAB dips 1.0% to $45.59, a 3-month low
- Closed at $45.59, -0.98% vs the prior close of $46.04. Day range $45.15–$46.12, opened at $45.53.
- Volume was 416.50K shares, 0.8x its 50-day average of 490.87K.
- Price is -15.6% vs its 50-day average ($54.03) and -7.5% vs its 200-day average ($49.30).
- 52-week range $20.18–$72.36; today's close sits at 49% of that range, 37.0% below the 52-week high.
Oct 12, 2026 — ANAB ends flat (+0.2%) to $46.04
- Closed at $46.04, +0.20% vs the prior close of $45.95. Day range $45.99–$46.78, opened at $46.16.
- Volume was 371.60K shares, 0.8x its 50-day average of 492.47K.
- Price is -15.0% vs its 50-day average ($54.19) and -6.5% vs its 200-day average ($49.24).
- 52-week range $20.18–$72.36; today's close sits at 50% of that range, 36.4% below the 52-week high.
Oct 9, 2026 — ANAB dips 0.6% to $45.95
- Closed at $45.95, -0.56% vs the prior close of $46.21. Day range $45.81–$47.19, opened at $46.11.
- Volume was 495.20K shares, 1.0x its 50-day average of 503.96K.
- Price is -15.4% vs its 50-day average ($54.34) and -6.6% vs its 200-day average ($49.18).
- 52-week range $20.18–$72.36; today's close sits at 49% of that range, 36.5% below the 52-week high.
Oct 8, 2026 — ANAB rises 1.2% to $46.21
- Closed at $46.21, +1.23% vs the prior close of $45.65. Day range $44.74–$46.77, opened at $45.36.
- Volume was 554.20K shares, 1.1x its 50-day average of 501.44K.
- Price is -15.2% vs its 50-day average ($54.52) and -5.9% vs its 200-day average ($49.12).
- 52-week range $20.18–$72.36; today's close sits at 50% of that range, 36.1% below the 52-week high.
Oct 7, 2026 — ANAB slides 4.7% to $45.65, a 3-month low
- Closed at $45.65, -4.68% vs the prior close of $47.89. Day range $45.62–$47.39, opened at $47.00.
- Volume was 766.50K shares, 1.5x its 50-day average of 496.55K.
- Price is -16.5% vs its 50-day average ($54.64) and -6.9% vs its 200-day average ($49.05).
- 52-week range $19.65–$72.36; today's close sits at 49% of that range, 36.9% below the 52-week high.
Oct 6, 2026 — ANAB dips 2.7% to $47.89, a 3-month low
- Closed at $47.89, -2.66% vs the prior close of $49.20. Day range $47.35–$49.41, opened at $49.41.
- Volume was 627.10K shares, 1.3x its 50-day average of 491.73K.
- Price is -12.6% vs its 50-day average ($54.77) and -2.2% vs its 200-day average ($48.98).
- 52-week range $19.65–$72.36; today's close sits at 54% of that range, 33.8% below the 52-week high.
Oct 5, 2026 — ANAB rises 1.4% to $49.20
- Closed at $49.20, +1.38% vs the prior close of $48.53. Day range $47.52–$49.84, opened at $48.53.
- Volume was 595.50K shares, 1.2x its 50-day average of 489.55K.
- Price is -10.4% vs its 50-day average ($54.88) and +0.6% vs its 200-day average ($48.89).
- 52-week range $19.65–$72.36; today's close sits at 56% of that range, 32.0% below the 52-week high.
Oct 2, 2026 — ANAB ends flat (-0.2%) to $48.53, a 3-month low, 6 down days in a row
- Closed at $48.53, -0.21% vs the prior close of $48.63. Day range $48.28–$49.83, opened at $48.97.
- Volume was 441.10K shares, 0.9x its 50-day average of 494.22K.
- Price is -11.7% vs its 50-day average ($54.98) and -0.5% vs its 200-day average ($48.80).
- 52-week range $19.65–$72.36; today's close sits at 55% of that range, 32.9% below the 52-week high.
- That makes 6 straight losses.
ANAB latest news & SEC filings
Every SEC filing by or about ANAB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Renton Hollings converted options/RSUs into 5,000 shares at $18.03 (≈$90.15K) on Oct 1, 2026; now holds 15,995
- Renton Hollings sold 5,000 shares at $49.87 (≈$249.37K) on Oct 1, 2026; now holds 10,995
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Exhibits / financial statements only (Item 9.01).
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Orwin John A converted options/RSUs into 1,300 shares on Sep 15, 2026; now holds 17,995
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 29, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Jun 29, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Jun 29, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Jun 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Things to know before you trade ANAB
- Last results release: May 12, 2026 (8-K Item 2.02). Previous ones: Mar 3, 2026, Jan 9, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Aug 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.95% (largest 5.8%).
- Liquidity: about 576.98K shares (≈$26.89M) trade per day on average.
- 52-week position: $46.61 vs a range of $20.18–$72.36 (51% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 15:10 on Apr 20, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: John P. Schmid sold 12,596 shares on Mar 30, 2026.
- Latest filings: 8-K Sep 21, 2026; 8-K Aug 11, 2026; 8-K Jul 30, 2026.
- Share count: 29.10M shares outstanding (May 7, 2026), -1.0% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ANAB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 48.56 | 48.56 | 46.46 | 46.61 | 413.63K |
| Oct 15, 2026 | 47.43 | 48.83 | 46.93 | 48.71 | 416.30K |
| Oct 14, 2026 | 45.25 | 47.24 | 45.00 | 46.67 | 494.10K |
| Oct 13, 2026 | 45.53 | 46.12 | 45.15 | 45.59 | 416.50K |
| Oct 12, 2026 | 46.16 | 46.78 | 45.99 | 46.04 | 371.60K |
| Oct 9, 2026 | 46.11 | 47.19 | 45.81 | 45.95 | 495.20K |
| Oct 8, 2026 | 45.36 | 46.77 | 44.74 | 46.21 | 554.20K |
| Oct 7, 2026 | 47.00 | 47.39 | 45.62 | 45.65 | 766.50K |
| Oct 6, 2026 | 49.41 | 49.41 | 47.35 | 47.89 | 627.10K |
| Oct 5, 2026 | 48.53 | 49.84 | 47.52 | 49.20 | 595.50K |
| Oct 2, 2026 | 48.97 | 49.83 | 48.28 | 48.53 | 441.10K |
| Oct 1, 2026 | 49.94 | 50.97 | 48.13 | 48.63 | 512.30K |
| Sep 30, 2026 | 50.13 | 52.02 | 49.39 | 50.26 | 1.43M |
| Sep 29, 2026 | 50.44 | 50.90 | 49.46 | 50.37 | 677.60K |
| Sep 28, 2026 | 51.00 | 51.65 | 50.50 | 50.80 | 412.60K |
| Sep 25, 2026 | 52.38 | 52.38 | 50.80 | 51.00 | 437.70K |
| Sep 24, 2026 | 50.59 | 52.16 | 50.35 | 51.70 | 417.80K |
| Sep 23, 2026 | 53.55 | 53.93 | 49.45 | 50.77 | 779.60K |
| Sep 22, 2026 | 55.07 | 56.04 | 50.61 | 53.92 | 755.70K |
| Sep 21, 2026 | 56.00 | 56.00 | 54.09 | 54.92 | 524.40K |
About Anaptysbio
Anaptysbio (ANAB) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends June 30. SEC CIK 1370053.
ANAB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Dennis M Fenton | Director | Jan 8, 2026 |
| Daniel Faga | President, CEO | Aug 7, 2026 |
| Susannah Gray | Director | Apr 29, 2026 |
| Owen Hughes | Director | May 13, 2026 |
| Rita Jain | Director | Jan 8, 2026 |
| Magda Marquet | Director | Jan 16, 2026 |
| John A Orwin | Director | Sep 17, 2026 |
| Hollings Renton | Director | Jun 17, 2026 |
| John P. Schmid | Director | Jun 17, 2026 |
| J. Anthony Ware | Director | Jan 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Daniel Faga | President, CEO | Aug 7, 2026 |
| Eric J Loumeau | CHIEF LEGAL OFFICER | Feb 13, 2026 |
| Paul F. Lizzul | Chief Medical Officer | Aug 7, 2026 |
| Dennis Mulroy | CHIEF FINANCIAL OFFICER | Jan 9, 2026 |
| Christopher M. Murphy | Chief Financial Officer | May 13, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 30, 2026 | John P. Schmid | Sale | 12,596 | $55.71 |
| Mar 30, 2026 | John P. Schmid | Sale | 7,527 | $56.70 |
| Mar 30, 2026 | John P. Schmid | Sale | 522 | $57.40 |
| Mar 30, 2026 | John P. Schmid | Sale | 12,596 | $55.71 |
| Mar 30, 2026 | John P. Schmid | Sale | 7,527 | $56.70 |
| Mar 30, 2026 | John P. Schmid | Sale | 522 | $57.40 |
| Mar 30, 2026 | John P. Schmid | Sale | 12,596 | $55.71 |
| Mar 30, 2026 | John P. Schmid | Sale | 7,527 | $56.70 |
| Mar 30, 2026 | John P. Schmid | Sale | 522 | $57.40 |
| Mar 30, 2026 | John P. Schmid | Sale | 12,596 | $55.71 |
| Mar 30, 2026 | John P. Schmid | Sale | 7,527 | $56.70 |
| Mar 30, 2026 | John P. Schmid | Sale | 522 | $57.40 |
| Mar 27, 2026 | Daniel Faga | Sale | 100 | $65.99 |
| Mar 27, 2026 | Daniel Faga | Sale | 3,038 | $65.20 |
| Mar 27, 2026 | Daniel Faga | Sale | 3,155 | $64.19 |
ANAB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $234.60M | $-13.23M | -0.46 | $19.70M |
| Dec 31, 2024 | $91.28M | $-145.23M | -5.12 | $-135.34M |
| Dec 31, 2023 | $17.16M | $-163.62M | -6.08 | $-120.80M |
| Dec 31, 2022 | $10.29M | $-128.72M | -4.57 | $-73.59M |
| Dec 31, 2021 | $63.17M | $-57.80M | -2.11 | $-45.92M |
Latest balance sheet: total assets $329.68M, total liabilities $—, cash $248.47M (as of Mar 31, 2026).
ANAB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| May 12, 2026 | 8-K Item 2.02 (results) | $65.58 |
| Mar 3, 2026 | 8-K Item 2.02 (results) | $35.22 |
| Jan 9, 2026 | 8-K Item 2.02 (results) | $29.78 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $23.16 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $15.03 |
| May 5, 2025 | 8-K Item 2.02 (results) | $13.82 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $10.93 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $13.25 |
| Aug 5, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 11, 2024 | 8-K Item 2.02 (results) | — |
| Jan 5, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ANAB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.